Mizejewski G J
Wadsworth Center, Division of Translational Medicine, New York State Department of Health, Empire State Plaza, Albany, NY, 12201, USA.
Tumour Biol. 2013 Jun;34(3):1317-36. doi: 10.1007/s13277-013-0704-4. Epub 2013 Feb 28.
The identification of a tumor cell receptor for alpha-fetoprotein (AFP) has long been sought in the field of medicine. The uptake and endocytosis of AFP by rat tumor cells in 1983 sparked a series of confirmatory reports which were extended to include multiple tumor types in rats, mice, and humans. The following year, French investigators characterized the binding properties of the AFP receptor but they did not purify and characterize the receptor. It was not until 1991-1992 that an AFP receptor was partially purified and characterized from both human monocytes and breast cancer cells. By 1993, monoclonal antibodies had been raised against the "AFP receptor" derived from breast cancer extracts with claims that the receptor was a widespread oncoprotein biomarker for cancer. To date, that receptor has yet to be identified due to its complex multimeric structure and carbohydrate composition. The present report will review the literature of the multiple AFP receptors previously including their cellular uptake, transmembrane passage, and partial biochemical characterization. . In addition, evidence derived from computer modeling, proteolytic/fragmentation cleavage patterns, domain structure analysis, and protein binding software analysis will be presented in a proposed identification of a widespread protein/gene family of transmembrane proteins which fits many, if not most, of the criteria attributed to the AFP receptor. The proposed receptor protein family is tentatively identified as an epithelial cell surface mucin constituting one (or more) of many classes of single-pass transmembrane proteins. Present data do not support the concept that the AFP receptor is a "universal" tumor receptor and/or biomarker, but rather a widespread mucin protein that functions primarily in protecting and lubricating epithelial mucosal layers, and engaging in signal transduction; the mucin only binds AFP as a molecule serving in a subordinate or ancillary function.
长期以来,医学领域一直在寻找甲胎蛋白(AFP)的肿瘤细胞受体。1983年大鼠肿瘤细胞对AFP的摄取和胞吞作用引发了一系列证实性报告,这些报告后来扩展到包括大鼠、小鼠和人类的多种肿瘤类型。次年,法国研究人员描述了AFP受体的结合特性,但他们并未对该受体进行纯化和特性鉴定。直到1991 - 1992年,才从人类单核细胞和乳腺癌细胞中对AFP受体进行了部分纯化和特性鉴定。到1993年,已经产生了针对源自乳腺癌提取物的“AFP受体”的单克隆抗体,并宣称该受体是一种广泛存在的癌症癌蛋白生物标志物。迄今为止,由于其复杂的多聚体结构和碳水化合物组成,该受体尚未被鉴定出来。本报告将回顾此前关于多种AFP受体的文献,包括它们的细胞摄取、跨膜转运以及部分生化特性。此外,将展示从计算机建模、蛋白水解/片段裂解模式、结构域结构分析和蛋白质结合软件分析中获得的证据,以提出对一种广泛存在的跨膜蛋白家族的鉴定,该家族符合许多(如果不是大多数)归因于AFP受体的标准。所提出的受体蛋白家族初步被鉴定为一种上皮细胞表面粘蛋白,它构成了多类单次跨膜蛋白中的一种(或多种)。目前的数据并不支持AFP受体是一种“通用”肿瘤受体和/或生物标志物的概念,而是一种广泛存在的粘蛋白,其主要功能是保护和润滑上皮粘膜层以及参与信号转导;该粘蛋白仅将AFP作为一种起次要或辅助作用的分子结合。